Rare Absence of CD79alpha in B-ALLs is not Associated with Altered Prognosis

Garg, Neha; Shastri, Malvika; kotru, Mrinalini; Gupta, Richa

doi:10.58209/ijbc.14.1.29

Volume 14, Issue 1 ( March 2022 2022) Iranian Journal of Blood and Cancer 2022, 14(1): 29-32 | Back to browse issues page

‎ 10.58209/ijbc.14.1.29

Mendeley

Zotero

RefWorks

Garg N, Shastri M, kotru M, Gupta R. Rare Absence of CD79alpha in B-ALLs is not Associated with Altered Prognosis. Iranian Journal of Blood and Cancer 2022; 14 (1) :29-32
URL: http://ijbc.ir/article-1-1024-en.html

Rare Absence of CD79alpha in B-ALLs is not Associated with Altered Prognosis

Neha Garg¹

, Malvika Shastri²

, Mrinalini Kotru³

, Richa Gupta ^*

⁴

1- senior Resident, Department of Pathology, UCMS and GTBH
2- Junior Resident,Department of Pathology, UCMS and GTBH
3- Professor, Department of Pathology, UCMS and GTBH
4- Professor, Department of Pathology, UCMS and GTBH , richagupta0209@gmail.com

Abstract: (1619 Views)

Background: The diagnosis of B-cell acute lymphoblastic leukemia (B-ALL) on the basis of the World Health Organization (WHO) recommendations in 2016 requires the expression of CD19 with CD79a (CD79a), cCD22 and CD10. CD79a is an integral B cell antigen expressed at all stages. Its absence in B-ALL has only been rarely reported. In this study, we described three cases of B-ALL showing complete loss or extremely weak expression of CD79a.
Methods: Seventy-five patients with B-ALL diagnosed by flow cytometry over a period of 3.5 years were taken out from the records. Cases lacking for CD79a by flow cytometry were further analysed.
Results: Out of 75 cases, CD 79a negativity was seen in 4% (3/75). However, every three cases expressed other B cell markers. No aberrant expression of myeloid and lymphoid antigens was seen in any of these three cases. The prognosis of these three cases was similar to CD79a positive cases.
Conclusion: Rarely, B cell ALL may lack CD79a. Thus, to avoid the misdiagnosis, a comprehensive antibody panel should be used. There was no prognostic impact of CD79a negativity in this study, however larger studies are needed to confirm these results.

Keywords: B-cell acute lymphoblastic leukemia, CD79a expression, Flow cytometry, Immunophenotyping, Prognosis

Full-Text [PDF 551 kb] (816 Downloads)

: Meta-analysis | Subject: Adults Hematology & Oncology
Received: 2020/06/19 | Accepted: 2022/03/11 | Published: 2022/04/30

References

1. Chiaretti S, Zini G, Bassan R. Diagnosis and subclassification of acute lymphoblastic leukemia. Mediterr J Hematol Infect Dis. 2014;6(1):e2014073. [DOI:10.4084/mjhid.2014.073]

2. Lai R, Juco J, Lee SF, Nahirniak S, Etches WS. Flow cytometric detection of CD79a expression in T-Cell acute lymphoblastic leukemias. Am J Clin Pathol. 2000; 113:823-30. [DOI:10.1309/391R-93YF-DB4D-1L35]

3. Swerdlow SH, Campo E, Harris NL, Jaffe ES, PileriSA, Stein H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC; 2008.

4. SeRdek Ł, Bulsa J, Sonsala A, Twardoch M, Wieczorek M, Malinowska I, et al. The immunophenotypes of blast cells in B cell precursor acute lymphoblastic leukemia: How different are they from their normal counterparts? Cytometry B Clin Cytom. 2014;86:329-39. [DOI:10.1002/cyto.b.21176]

5. Gujral S, Badrinath Y, Kumar A, Subramanian PG, Raje G, Jain H, et al. Immunophenotypic profile of acute leukemia: Critical analysis and insights gained at a tertiary care center in India. Cytometry B Clin Cytom. 2009;76:199-205. [DOI:10.1002/cyto.b.20451]

6. Garg N, Kotru M, Kumar D, Pathak R, Sikka M. Correlation of expression of aberrant immunophenotypic markers in T-ALL with its morphology: A pilot study. J Lab Physicians. 2018; 10:410-13. [DOI:10.4103/JLP.JLP_35_18]

7. Solano-Genesta M, Tar_ın-Arzaga L, Velasco-Ruiz I, Lutz-Presno JA, Gonz_alez-Llano O, et al. CD20 expression in B-cell precursor acute lymphoblastic leukemia is common in Mexican patients and lacks a prognostic value. Hematology. 2012; 17:66-70. [DOI:10.1179/102453312X13221316477741]

8. Jeha S, Behm F, Pei D, Sandlund JT, Ribeiro RC, Razzouk BI, et al. Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia. Blood. 2006; 108:3302-4. [DOI:10.1182/blood-2006-04-016709]

9. Borst J, Brouns GS, de Vries E, Verschuren MC, Mason DY, van Dongen JJ. Antigen receptors on T and B lymphocytes: parallels in organization and function. Immunol Rev. 1993; 132:49-84. [DOI:10.1111/j.1600-065X.1993.tb00837.x]

10. Dworzak MN, Fritsch G, Froschl G, Printz D, Gadner H. Four-color flow cytometric investigation of terminal deoxynucleotidyl transferase-positive lymphoid precursors in pediatric bone marrow: CD79a expression precedes CD19 on early B-cell ontogeny. Blood. 1998; 92:3203-9. [DOI:10.1182/blood.V92.9.3203]

11. Sakaguchi N, Kashiwamura S, Kimoto M, Thalmann P, Melchers F. B lymphocyte lineage-restricted expression of mb-1, a gene with CD3-like structural properties. EMBO J. 1988;7: 3457-64. [DOI:10.1002/j.1460-2075.1988.tb03220.x]

12. Mason DY, Cordell JL, Brown MH, Borst J, Jones M, Pulford K, et al. CD79a: a novel marker for B-cell neoplasms in routinely processed tissue samples. Blood. 1995; 86:1453-9. [DOI:10.1182/blood.V86.4.1453.bloodjournal8641453]

13. Erickson LD, Tygrett LT, Bhatia SK, Grabstein KH, Waldschmidt TJ. Differential expression of CD22 (Lyb8) on murine B cells. Int Immunol. 1996; 8:1121- 9. [DOI:10.1093/intimm/8.7.1121]

14. Nasr MR, Rosenthal N, Syrbu S. Expression profiling of transcription factors in B- or T-acute lymphoblastic leukemia/lymphoma and burkitt lymphoma: usefulness of PAX5 immunostaining as pan-PreB-cell marker. Am J Clin Pathol. 2010;133(1):41-8. [DOI:10.1309/AJCPYP00JNUFWCCY]

15. Adams H, Liebisch P, Schmid P, Dirnhofer S, Tzankov A. Diagnostic utility of the B-cell lineage markers CD20, CD79a, PAX5, and CD19 in paraffinembedded tissues from lymphoid neoplasms. Appl Immunohistochem Mol Morphol. 2009;17(2):96-101. [DOI:10.1097/PAI.0b013e3181845ef4]

16. Dakka N, Bellaoui H, Bouzid N, Khattab M, Bakri Y, Benjouad A. CD10 AND CD34 expression in childhood acute lymphoblastic leukemia in Morocco: clinical relevance and outcome. Pediatr Hematol Oncol. 2009;26(4):216-31. [DOI:10.1080/07357900902897557]

Send email to the article author

Rights and permissions
	This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Designed & Developed by : Yektaweb